Wellington Management Group LLP Decreases Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Wellington Management Group LLP trimmed its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 77.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,506,138 shares of the life sciences company's stock after selling 8,417,221 shares during the quarter. Wellington Management Group LLP owned 3.25% of Integra LifeSciences worth $56,839,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC boosted its stake in shares of Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after purchasing an additional 2,800 shares during the last quarter. Empowered Funds LLC acquired a new position in Integra LifeSciences during the fourth quarter worth $180,000. Centiva Capital LP purchased a new stake in shares of Integra LifeSciences in the third quarter valued at about $192,000. Mitsubishi UFJ Asset Management UK Ltd. purchased a new stake in shares of Integra LifeSciences in the fourth quarter valued at about $204,000. Finally, Romano Brothers AND Company purchased a new stake in shares of Integra LifeSciences in the fourth quarter valued at about $204,000. 84.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $23.00.

Integra LifeSciences Price Performance

IART traded down $1.59 on Thursday, reaching $17.60. The company had a trading volume of 93,613 shares, compared to its average volume of 1,045,768. The business has a 50 day simple moving average of $22.63 and a 200 day simple moving average of $22.31. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -197.76, a P/E/G ratio of 0.73 and a beta of 1.24. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $34.41.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.85 by $0.12. The firm had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business's revenue was up 11.5% compared to the same quarter last year. During the same period last year, the firm posted $0.89 earnings per share. As a group, sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.